{"id":"gsk2269557","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL5314409","moleculeType":"Small molecule","molecularWeight":"477.01"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting HDAC6, GSK2269557 modulates protein acetylation levels, which can affect cellular processes such as protein degradation and cytoskeletal dynamics.","oneSentence":"GSK2269557 is a selective inhibitor of the histone deacetylase 6 (HDAC6).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:40:01.477Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors"}]},"trialDetails":[{"nctId":"NCT02522299","phase":"PHASE2","title":"A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":44},{"nctId":"NCT02294734","phase":"PHASE2","title":"An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-31","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":126},{"nctId":"NCT03345407","phase":"PHASE2","title":"Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":943},{"nctId":"NCT02593539","phase":"PHASE2","title":"Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-07-22","conditions":"Activated PI3K-delta Syndrome","enrollment":5},{"nctId":"NCT03315559","phase":"PHASE1","title":"Absorption & Elimination of Radiolabelled GSK2269557","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-11-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":6},{"nctId":"NCT03189589","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":12},{"nctId":"NCT02130635","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-31","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":64},{"nctId":"NCT02567708","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":50},{"nctId":"NCT01462617","phase":"PHASE1","title":"Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-24","conditions":"Asthma","enrollment":61},{"nctId":"NCT01762878","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":45},{"nctId":"NCT02691325","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22},{"nctId":"NCT02972905","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GSK2269557","genericName":"GSK2269557","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK2269557 is a selective inhibitor of the histone deacetylase 6 (HDAC6). Used for Advanced solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}